Serum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients.

patients with underlying diseases or of older age were more likely to have elevated levels of PCT and IL-6; however, age did not reach statistical significance in our dataset.

also in 111,027 other papers